A Single and Low Dose of Recombinant Factor VIIa in Patients With Severe Factor XI Deficiency Undergoing Surgery

• Status: Unknown status
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Lately the investigators found that patients with severe factor XI deficiency and inhibitors could undergo major surgery with a single low dose of recombinant factor VIIa and tranexamic agent. These results encourage us to apply this treatment in clinical trial setting to patients with severe factor XI deficiency undergoing surgery instead of blood product.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center

Criteria

Inclusion Criteria:

• patients with severe factor XI deficiency who will give informed consent to participate in the study

Exclusion Criteria:

• patients with atherosclerosis disease i.e. unstable angina pectoris or recent stroke

• Patients who required aorto-coronary bypass or any vascular surgery